(Q83967551)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

title

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

main subject

acute myeloid leukemia

1 reference

inferred from title

author

María-Belén Vidriales

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Stéphane de Botton

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Charles Dumontet

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Jesús San Miguel

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Simona Lapusan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Xavier Thomas

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Anne Vekhoff

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Ruoping Tang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Rodica Morariu-Zamfir

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

John M Lambert

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Marie-Laure Ozoux

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Philippe Poncelet

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Ollivier Legrand

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Daniel J DeAngelo

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Francis J Giles

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Jean-Pierre Marie

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

26 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

29 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

1121-1131

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21519855%20AND%20SRC:MED&resulttype=core&format=json

Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.

29 January 2020

cites work

1 reference

12 December 2020

Analysis of P-glycoprotein-mediated membrane transport in human peripheral blood lymphocytes using the UIC2 shift assay.

1 reference

12 December 2020

Acute leukemia in adolescents and young adults

1 reference

12 December 2020

P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients

1 reference

12 December 2020

Prognostic value of S-phase cells in AML patients

1 reference

12 December 2020

Antimitotic Activity of the Potent Tumor Inhibitor Maytansine

1 reference

12 December 2020

Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus

1 reference

12 December 2020

Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate

1 reference

12 December 2020

The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score

1 reference

12 December 2020

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

1 reference

12 December 2020

1 reference

12 December 2020

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

12 December 2020

Acute myeloid leukemia in the elderly

1 reference

12 December 2020

Acute myelogenous leukemia

1 reference

12 December 2020

Binding of maytansine to tubulin: competition with other mitotic inhibitors

1 reference

12 December 2020